the fresenius prophylaxis in catheter locking · 4% citrate the fresenius prophylaxis in catheter...
TRANSCRIPT
4% Citrate
The Fresenius Prophylaxis in Catheter LockingIntraLock®: Building on reliability and cost-effectiveness.
4% Citrate – recommended by
ERBP position statement 3
Advantages in catheter locking vs. Heparin
• Longer intervention-free period1
• Lower need for thrombolytic agents1
• No heparin associated bleeding complications2
• Provides reliable anti-thrombotic effect1
A reliable locking solution …
Higher survival probability of Central Venous Catheters (CVC) with 4% Citrate vs Heparin
0 11 23 33 42 54 66 80 89 101
114
128
144
162
180
194
213
239
Days
4% CitrAte is recommended by ERBP and ASDIN position statement 3
1.0
0.8
0.6
0.4
0.2
0
Pro
babi
lilty
of n
o C
VC
exc
hang
e
Adapted from Lok 20071
4% Citrate
Heparin
P = 0.042
1 box contains 10 x 5 ml
… with an excellent cost profile.
Advantages in catheter locking vs. hypertonic Citrate solutions
• Minimized risk for systemic hypocalcemia and its consequences (arrythmia, cardiac arrest)2
• Offers best risk/benefit ratio of Citrate locking solutions3
Needle-free ampoules
F000
0368
0 G
B (J
NB
MC
CA
NN
02.
13) ©
Cop
yrig
ht 2
013
Fres
eniu
s M
edic
al C
are
Deu
tsch
land
Gm
bH
Literature References
1 Lok C, et al. Trisodium citrate 4 % – an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant. 2007;22:477–483.2 Grudzinski L, et al. Sodium citrate 4 % locking solution for central venous dialysis catheters – an effective, more cost efficient alternative to heparin, Nephrol Dial
Transplant. 2007;22:471–476.3 Vanholder R, et al. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European
Renal Best Practice (ERBP), Nephrol Dial Transplant. 2010;3:234–246.
A reliable locking solution with an excellent cost profile.
4% Citrate as in IntraLock® offers
• Longer intervention-free period compared to Heparin1
• Efficient coagulation prophylaxis1 – at the best risk/benefit ratio of Citrate locking solutions3
• An excellent cost profile – allowing an economic catheter care management
4% Citrate
Fresenius Medical Care Deutschland GmbH · Renal PharmaElse-Kröner-Straße 1 · 61352 Bad Homburg v. d. H. · GermanyPhone: +49 (0) 6172-609-0 · Fax: +49 (0) 6172-609-5638 [email protected] · www.fmc-renalpharma.com